News Quantified

AGIO – agios pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

Agios Pharmaceuticals, Inc. (AGIO): A Bull Case Theory [Yahoo! Finance]

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

What Catalysts Are Rewriting The Story For Agios Pharmaceuticals (AGIO)? [Yahoo! Finance]

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by analysts at JPMorgan Chase & Co. from $20.00 to $25.00. They now have a "neutral" rating on the stock.

2.9%

BEAT

-0.5%

MISS

1.1%

BEAT

Leerink Partners

Form 8-K AGIOS PHARMACEUTICALS, For: Jan 12

Form 4 AGIOS PHARMACEUTICALS, For: Jan 05 Filed by: Milanova Tsveta

Form 144 AGIOS PHARMACEUTICALS, Filed by: Milanova Tsveta

Form 4 AGIOS PHARMACEUTICALS, For: Dec 30 Filed by: Burns James William

Form 4 AGIOS PHARMACEUTICALS, For: Dec 30 Filed by: Goff Brian

Top News Gainers

1/13 Form 8-K AGIOS PHARMACEUTICALS, For: Jan 13 8.7%

11/5 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its price target lowered by analysts at Citigroup Inc from $80.00 to $64.00. They now have a "buy" rating on the stock. 7.9%

9/10 Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO 6.2%

10/2 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.6%

12/9 Form 8-K AGIOS PHARMACEUTICALS, For: Dec 08 5.4%

6/14 Form 4 AGIOS PHARMACEUTICALS For: Jun 12 Filed by: MARAGANORE JOHN 5.4%

2/13 Q4/2019 12/31/2019 EPS -1.600 ZacksConsensus -1.780 ActVsEst 0.180 - Beat 5.3%

7/30 Agios Pharmaceuticals Inc (NASDAQ: AGIO) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 5.1%

5/15 Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients 5.0%

4/16 Form DEF 14A AGIOS PHARMACEUTICALS, For: May 28 5.0%

Top News Decliners

5/1 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $72.00 price target on the stock. -13.0%

8/1 Form 10-Q AGIOS PHARMACEUTICALS, For: Jun 30 -11.2%

12/9 Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML) -8.8%

5/16 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Cowen Inc. -7.9%

4/30 Agios Pharmaceuticals Inc (NASDAQ: AGIO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.6%

1/13 TIO Bioventures Launches Treadwell Therapeutics, Seeded With $27m to Develop First-in-Class Oral Medicines Against Novel Targets -6.2%

10/28 Form 8-K AGIOS PHARMACEUTICALS, For: Oct 27 -6.2%

9/30 Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients -6.2%

2/24 Form 4 AGIOS PHARMACEUTICALS, For: Feb 20 Filed by: Alenson Carman -6.0%

2/14 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "hold" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. -5.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day